PRZOOM - /newswire/ -
Palo Alto, CA, United States, 2007/04/17 - New analysis from Frost & Sullivan, U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets, reveals that the market earned revenues of $5.90 billion in 2006 and estimates this to reach $10.17 billion in 2013.
A rapidly ageing population is driving the need for effective pain management therapies for acute and chronic pain. Since there is considerable unmet medical need in the treatment of pain, newer and more effective therapies will be welcome in the opioid and non-opioid pain management pharmaceuticals market.
New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets, reveals that the market earned revenues of $5.90 billion in 2006 and estimates this to reach $10.17 billion in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.
The significant recall of Vioxx and Bextra from the market, coupled with the robust demand for pain management therapies, is creating substantial opportunities for novel therapies in the opioid and non-opioid pain management markets. However, there have been no blockbuster drugs to fill the gap created by their exit and non-opioid therapies have extensively available generics.
Despite the lack of major breakthrough therapies, specialty pharma and drug delivery companies have successfully engaged in lifecycle management partnerships to relaunch older therapies in newer formulations.
“Noting the remarkable market potential, several “Big Pharma”, specialty pharmaceutical, and drug delivery companies have been planning for market expansion, thereby driving market growth,” says Frost & Sullivan Research Analyst Barath Shankar S.
To sustain this growth momentum, market participants must pay attention to the increasing apprehensions regarding the safety profile of opioid and non-opioid therapies. The escalating regulatory and media scrutiny on opioid therapies have compelled drug companies to address the issue of potential drug abuse.
“The collaborations between pharmaceuticals and drug delivery companies have ensured that next-generation drugs have abuse- and tamper-resistant formulations,” notes Shankar. “Market participants can promote this benefit to not only expand their customer base but also meet the increasingly stringent regulatory norms.”
The U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets is part of the Pharmaceutical and Biotechnology Growth Partnership Service, which also includes research in the following markets: U.S. pulmonary arterial hypertension markets, analysis of top 10 specialty pharmaceutical companies, and U.S. drug discovery contract research organization markets. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership service, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.